Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is Verici Dx in Focus? Fundraising announcement puts diagnostic development funding in focus (LSE:VRCI)

Verici Dx — LSE:VRCI — is in focus after the latest corporate development: Fundraising announcement puts diagnostic development funding in focus. The company is traded on the London Stock Exchange’s AIM market, rather than being a constituent of the FTSE 100 or FTSE 250. …

Ankur Sharma | 09 October 2026

Why Is ECO Animal Health Group in Focus? Shareholding notification updates the ownership picture (LSE:EAH)

ECO Animal Health Group — LSE:EAH — is in focus after the latest corporate development: Shareholding notification updates the ownership picture. The company is traded on the London Stock Exchange’s AIM market, rather than being a constituent of the FTSE 100 or FTSE 250. …

Ankur Sharma | 09 October 2026

Advanced Medical Solutions Group: What Does the Latest Corporate Update Mean for Investors? (LSE:AMS)

Advanced Medical Solutions Group is in focus following investor disclosure and corporate updates. The announcement matters because it may influenceShareholderexpectations,Capitalallocation, governance or the company’s strategic direction. Investors should separate the confirmed transaction or disclosure from assumptions about future performance.

Ankur Sharma | 09 October 2026

What to Expect From Tristel (LSE:TSTL) as Full-Year Results Near on the FTSE AIM All Share Index

Tristel develops and manufactures infection prevention products based on its proprietary chlorine dioxide chemistry. Its main market is the decontamination of reusable medical devices that cannot be sterilised by heat, such as ultrasound probes and endoscopes, which are used in hospitals and clinics. The …

Ankur Sharma | 08 October 2026

How ValiRx (LSE:VAL) Is Reshaping Its Pipeline on the FTSE AIM All Share Index

ValiRx describes itself as focused on early-stage cancer therapeutics and women's health. Its model is to select and develop drug candidates and then partner or out-license them, often through dedicated subsidiaries. Its research arm, Inaphaea BioLabs, holds a biobank of patient-derived cell models and …

Ankur Sharma | 08 October 2026

What a CEO Succession and Buyback Mean for Venture Life (LSE:VLG) on the FTSE AIM All Share Index

Taken together, the announcements mark a period of transition for the group, withLeadershipchange coinciding with an activeCapitalreturn programme.

Ankur Sharma | 08 October 2026

Why Verici Dx (LSE:VRCI) Is in Focus on the FTSE AIM All Share Index This Week

Verici Dx develops and sells RNA-based tests designed to help clinicians manage kidney transplant patients. Its lead commercial product, Tutivia, is a blood test for acute rejection after a kidney transplant in the United States, and it runs tests through its own CLIA-certified, CAP-accredited …

Ankur Sharma | 08 October 2026

What the Sanmirna Deal Means for Thalia Therapeutics (LSE:THAT) on the FTSE AIM All Share Index

Thalia is a biotechnology company focused on RNA-based therapies. Before its rebrand, theBusinessoperated as N4 Pharma, which had been developing Nuvec, a delivery technology for nucleic acid medicines. The company announced the appointment of a new chief executive alongside a proposed name change, a …

Ankur Sharma | 08 October 2026

How TheraCryf (LSE:TCF) Is Moving Ox-1 Towards the Clinic on the FTSE AIM All Share Index

TheraCryf is a biotechnology company based at Alderley Park in Cheshire. It develops medicines for addiction and other neuropsychiatric disorders using a capital-light, virtual model, aiming to advance programmes to early clinical or proof-of-concept stage before partnering them with larger pharmaceutical or biotech groups.

Ankur Sharma | 08 October 2026

What Shield Therapeutics (LSE:STX) Reported in Its Interims on the FTSE AIM All Share Index

The company's recent reporting showed that Shield had reachedCash Flowpositivity asRevenuegrew, and that its loss had shrunk as milestone andRoyaltyreceipts increased. The shares jumped 11 per cent on one occasion as losses narrowed and the company held its profitability target.

Ankur Sharma | 08 October 2026
Support

Hi! How can we help you today?

Loading…